UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
(Mark One)
For the quarterly period ended
OR
For the transition period from ________ to__________
Commission file number:
(Exact Name of Registrant as Specified in Its Charter)
| (State or Other Jurisdiction of Incorporation or Organization) | (I.R.S. Employer Identification No.) |
| (Address of Principal Executive Offices) | (Zip Code) |
(Registrant’s Telephone Number, Including Area Code)
(Former Name, Former Address and Former Fiscal Year, if Changed Since Last Report)
Indicate by check mark whether the registrant:
(1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months
(or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements
for the past 90 days. Yes ☐
Indicate by check mark whether the registrant
has submitted electronically if any, every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during
the preceding 12 months (or for such shorter period that the registrant was required to submit such files).
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See definitions of “large accelerated filer”, “accelerated filer”, “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
| Large Accelerated Filer ☐ | Accelerated Filer ☐ |
| Smaller Reporting Company | |
| Emerging Growth Company |
If an emerging growth company, indicate by check
mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act.
Securities registered pursuant to Section 12(b) of the Exchange Act:
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||
| The |
Indicate by check mark whether the registrant
is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐
The registrant had
TABLE OF CONTENTS
i
CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS
We make forward-looking statements under the “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and in other sections of this Form 10-Q. In some cases, you can identify these statements by forward-looking words such as “may,” “might,” “should,” “would,” “could,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “predict,” “potential” or “continue,” and the negative of these terms and other comparable terminology. These forward-looking statements, which are subject to known and unknown risks, uncertainties and assumptions about us, may include projections of our future financial performance based on our growth strategies and anticipated trends in our business. These statements are only predictions based on our current expectations and projections about future events. There are important factors that could cause our actual results, level of activity, performance or achievements to differ materially from the results, level of activity, performance or achievements expressed or implied by the forward-looking statements.
While we believe we have identified material risks, these risks and uncertainties are not exhaustive. Other sections of this Form 10-Q may describe additional factors that could adversely impact our business and financial performance. Moreover, we operate in a very competitive and rapidly changing environment. New risks and uncertainties emerge from time to time, and it is not possible to predict all risks and uncertainties, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements.
Although we believe the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, level of activity, performance or achievements. Moreover, neither we nor any other person assumes responsibility for the accuracy or completeness of any of these forward-looking statements. You should not rely upon forward-looking statements as predictions of future events. We are under no duty to update any of these forward-looking statements after the date of this Form 10-Q to conform our prior statements to actual results or revised expectations, and we do not intend to do so.
We caution you not to place undue reliance on the forward-looking statements, which speak only as of the date of this Form 10-Q in the case of forward-looking statements contained in this Form 10-Q.
You should not rely upon forward-looking statements as predictions of future events. Our actual results and financial condition may differ materially from those indicated in the forward-looking statements. We qualify all of our forward-looking statements by these cautionary statements. Although we believe that the expectations reflected in the forward looking-statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements. Therefore, you should not rely on any of the forward-looking statements. In addition, with respect to all of our forward-looking statements, we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995.
ii
PART I - FINANCIAL INFORMATION
Item 1. Condensed Consolidated Financial Statements.
Bluejay Diagnostics, Inc.
Condensed Consolidated Balance Sheets
(Unaudited)
| September 30, | December 31, | |||||||
| 2021 | 2020 | |||||||
| ASSETS | ||||||||
| Current assets: | ||||||||
| Cash and cash equivalents | $ | $ | ||||||
| Inventory | ||||||||
| Deferred offering costs | ||||||||
| Prepaid expenses and other current assets | ||||||||
| Total current assets | ||||||||
| Property and equipment, net | ||||||||
| Total assets | $ | $ | ||||||
| LIABILITIES, REDEEMABLE PREFERRED STOCK AND STOCKHOLDERS’ DEFICIT | ||||||||
| Current liabilities: | ||||||||
| Accounts payable | $ | $ | ||||||
| Due to related party | ||||||||
| Accrued expenses | ||||||||
| Notes payable, net | ||||||||
| Convertible debentures | ||||||||
| Note payable, Paycheck Protection Program | ||||||||
| Derivative warrant liability | ||||||||
| Total liabilities | ||||||||
| Commitments and Contingencies (See Note 6) | ||||||||
| Series A redeemable, convertible preferred stock, $ | ||||||||
| Series B redeemable, convertible preferred stock, $ | ||||||||
| Series C redeemable, convertible preferred stock, $ | ||||||||
| Stockholders’ deficit: | ||||||||
| Common stock, $ | ||||||||
| Additional paid-in capital | ||||||||
| Accumulated deficit | ( | ) | ( | ) | ||||
| Total stockholders’ deficit | ( | ) | ( | ) | ||||
| Total liabilities, redeemable, convertible preferred stocks and stockholders’ deficit | $ | $ | ||||||
See notes to unaudited condensed consolidated financial statements.
Reflects a 1-for-3.15 stock dividend effective June 7, 2021.
1
Bluejay Diagnostics, Inc.
Condensed Consolidated Statements of Operations
(Unaudited)
| Three Months Ended September 30, | Nine Months Ended September 30, | |||||||||||||||
| 2021 | 2020 | 2021 | 2020 | |||||||||||||
| Operating expenses: | ||||||||||||||||
| Research and development | $ | $ | $ | $ | ||||||||||||
| General and administrative | ||||||||||||||||
| Marketing and business development | ||||||||||||||||
| Total operating expenses | ||||||||||||||||
| Operating loss | ( | ) | ( | ) | ( | ) | ( | ) | ||||||||
| Other income (expense): | ||||||||||||||||
| Derivative warrant liability gain (loss) | ( | ) | ||||||||||||||
| Interest income (expense), net of amortization of premium | ( | ) | ( | ) | ||||||||||||
| State grant revenue | ||||||||||||||||
| Other income | ||||||||||||||||
| Total other income (expense), net | ( | ) | ( | ) | ||||||||||||
| Net loss | $ | ( | ) | $ | ( | ) | $ | ( | ) | $ | ( | ) | ||||
| Net loss per share - Basic and diluted | $ | ( | ) | $ | ( | ) | $ | ( | ) | $ | ( | ) | ||||
| Weighted average common shares outstanding: | ||||||||||||||||
| Basic and diluted | ||||||||||||||||
See notes to unaudited condensed consolidated financial statements.
Reflects a 1-for-3.15 stock dividend effective June 7, 2021.
2
Bluejay Diagnostics, Inc.
Condensed
Consolidated Statements of Changes in Redeemable Preferred Stock and Stockholders’ Deficit
(Unaudited)
| Redeemable, Convertible Preferred Stock | Stockholders Deficit | |||||||||||||||||||||||||||||||||||||||||||
| Additional | Total | |||||||||||||||||||||||||||||||||||||||||||
| Series A | Series B | Series C | Common Stock | Paid-In | Accumulated | Stockholders’ | ||||||||||||||||||||||||||||||||||||||
| Shares | Amount | Shares | Amount | Shares | Amount | Shares | Amount | Capital | Deficit | Deficit | ||||||||||||||||||||||||||||||||||
| Balance at December 31, 2020 | $ | $ | $ | $ | $ | $ | ( | ) | $ | ( | ) | |||||||||||||||||||||||||||||||||
| Accretion of redeemable, convertible preferred stock to redemption value | - | - | - | - | ( | ) | ( | ) | ||||||||||||||||||||||||||||||||||||
| Stock-based compensation expense | - | - | - | - | ||||||||||||||||||||||||||||||||||||||||
| Fair value of warrants issued for services | - | - | - | - | ||||||||||||||||||||||||||||||||||||||||
| Net loss | - | - | - | - | - | ( | ) | ( | ) | |||||||||||||||||||||||||||||||||||
| Balance at March 31, 2021 | $ | $ | $ | $ | $ | $ | ( | ) | $ | ( | ) | |||||||||||||||||||||||||||||||||
| Accretion of redeemable, convertible preferred stock to redemption value | - | - | - | - | ( | ) | ( | ) | ||||||||||||||||||||||||||||||||||||
| Stock-based compensation expense | - | - | - | - | ||||||||||||||||||||||||||||||||||||||||
| Exercise of common stock warrants | - | - | - | - | - | - | ||||||||||||||||||||||||||||||||||||||
| preferred stock into common stock | ( | ) | ( | ) | ( | ) | ( | ) | ( | ) | ( | ) | ||||||||||||||||||||||||||||||||
| Conversion of Amended 2017 Convertible Notes | - | - | - | |||||||||||||||||||||||||||||||||||||||||
| Reclassification of Series B Warrants | - | - | - | - | ||||||||||||||||||||||||||||||||||||||||
| Net loss | - | - | - | - | ( | ) | ( | ) | ||||||||||||||||||||||||||||||||||||
| Balance at June 30, 2021 | $ | $ | $ | $ | $ | $ | ( | ) | $ | ( | ) | |||||||||||||||||||||||||||||||||
| Stock-based compensation expense | - | - | - | - | ||||||||||||||||||||||||||||||||||||||||
| Fair value of warrants issued to placement agent in relation to the Convertible debentures | - | - | - | - | ||||||||||||||||||||||||||||||||||||||||
| Issuance of common stock from exercise of employee stock options | - | - | - | |||||||||||||||||||||||||||||||||||||||||
| Net loss | - | - | - | - | ( | ) | ( | ) | ||||||||||||||||||||||||||||||||||||
| Balance at September 30, 2021 | - | $ | - | $ | - | $ | $ | $ | $ | ( | ) | $ | ( | ) | ||||||||||||||||||||||||||||||
3
Bluejay Diagnostics, Inc.
Condensed Consolidated Statements of Changes in Redeemable Preferred
Stock and Stockholders’ Deficit — (continued)
(Unaudited)
| Redeemable, Convertible Preferred Stock | Stockholders Deficit | |||||||||||||||||||||||||||||||||||||||||||
| Additional | Total | |||||||||||||||||||||||||||||||||||||||||||
| Series A | Series B | Series C | Common Stock | Paid-In | Accumulated | Stockholders’ | ||||||||||||||||||||||||||||||||||||||
| Shares | Amount | Shares | Amount | Shares | Amount | Shares | Amount | Capital | Deficit | Deficit | ||||||||||||||||||||||||||||||||||
| Balance at December 31, 2019 | $ | $ | $ | $ | $ | $ | ( | ) | $ | ( | ) | |||||||||||||||||||||||||||||||||
| Issuance of Series B redeemable, convertible preferred stock, net of issuance costs of $ | ||||||||||||||||||||||||||||||||||||||||||||
| Issuance of Series C redeemable, convertible preferred stock, net of issuance costs of $ | - | - | - | - | - | - | - | - | - | |||||||||||||||||||||||||||||||||||
| Reclassification of derivative warrant liability | - | - | ( | ) | - | - | ||||||||||||||||||||||||||||||||||||||
| Accretion of redeemable, convertible preferred stock to redemption value | - | - | - | - | ( | ) | ( | ) | ||||||||||||||||||||||||||||||||||||
| Stock-based compensation benefit | - | - | - | - | ( | ) | ( | ) | ||||||||||||||||||||||||||||||||||||
| Net loss | - | - | - | - | ( | ) | ( | ) | ||||||||||||||||||||||||||||||||||||
| Balance at March 31, 2020 | $ | $ | $ | $ | $ | $ | ( | ) | $ | ( | ) | |||||||||||||||||||||||||||||||||
| Accretion of redeemable, convertible preferred stock to redemption value | - | - | - | - | ( | ) | ( | ) | ||||||||||||||||||||||||||||||||||||
| Stock-based compensation expense | - | - | - | - | ||||||||||||||||||||||||||||||||||||||||
| Net loss | - | - | - | - | ( | ) | ( | ) | ||||||||||||||||||||||||||||||||||||
| Balance at June 30, 2020 | $ | $ | $ | $ | $ | $ | ( | ) | $ | ( | ) | |||||||||||||||||||||||||||||||||
| Issuance of Series B redeemable, convertible preferred stock | - | - | - | - | - | - | - | - | - | |||||||||||||||||||||||||||||||||||
| Reclassification of derivative warrant liability | - | - | ( | ) | - | - | ||||||||||||||||||||||||||||||||||||||
| Accretion of redeemable, convertible preferred stock to redemption value | - | - | - | - | ( | ) | ( | ) | ( | ) | ||||||||||||||||||||||||||||||||||
| Stock-based compensation expense | - | - | - | - | ||||||||||||||||||||||||||||||||||||||||
| Net loss | - | - | - | - | ( | ) | ( | ) | ||||||||||||||||||||||||||||||||||||
| Balance at September 30, 2020 | $ | $ | $ | $ | $ | $ | ( | ) | $ | ( | ) | |||||||||||||||||||||||||||||||||
See notes to unaudited condensed consolidated financial statements.
Reflects a 1-for-3.15 stock dividend effective June 7, 2021.
4
Bluejay Diagnostics, Inc.
Condensed Consolidated
Statements of Cash Flows
(Unaudited)
| Nine Months Ended September 30, | ||||||||
| 2021 | 2020 | |||||||
| CASH FLOWS FROM OPERATING ACTIVITIES: | ||||||||
| Net Loss | $ | ( | ) | $ | ( | ) | ||
| Adjustments to reconcile net loss to net cash used in operating activities: | ||||||||
| Depreciation expense | ||||||||
| Stock-based compensation expense | ||||||||
| Gain on forgiveness of note payable, Paycheck Protection Program | ( | ) | ||||||
| Non-cash interest expense | ( | ) | ||||||
| (Gain) loss on revaluation of derivative warrant liability | ( | ) | ||||||
| Changes in operating assets and liabilities: | ||||||||
| Accounts receivable | ||||||||
| Inventory | ( | ) | ||||||
| Prepaid expenses and other current assets | ( | ) | ||||||
| Accounts payable | ( | ) | ||||||
| Due to related party | ( | ) | ||||||
| Accrued expenses | ||||||||
| Net cash used in operating activities | ( | ) | ( | ) | ||||
| CASH FLOWS FROM INVESTING ACTIVITIES: | ||||||||
| Purchase of property and equipment | ( | ) | ||||||
| CASH FLOWS FROM FINANCING ACTIVITIES: | ||||||||
| Payments of principal on notes payable | ( | ) | ||||||
| Payments of convertible debenture issuance costs | ( | ) | ||||||
| Payments of deferred offering costs | ( | ) | ||||||
| Proceeds from issuance of convertible debentures | ||||||||
| Proceeds from issuance of Series B redeemable, convertible preferred stock, net of issuance costs | ||||||||
| Proceeds from subscription to the 2020 Promissory Notes | ||||||||
| Proceeds (payments) on note payable, Paycheck Protection Program | ( | ) | ||||||
| Proceeds from exercise of stock options | ||||||||
| Net cash provided by financing activities | ||||||||
| Increase (decrease) in cash and cash equivalents | ( | ) | ||||||
| Cash and cash equivalents, beginning of period | ||||||||
| Cash and cash equivalents, end of period | $ | $ | ||||||
| SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION AND NON-CASH FINANCING ACTIVITIES | ||||||||
| Interest paid | $ | $ | ||||||
| Accretion of Series A redeemable, convertible preferred stock dividend | $ | $ | ||||||
| Accretion of Series A redeemable, convertible preferred stock issuance costs | ||||||||
| and fair value adjustment | $ | $ | ||||||
| Accretion of Series B redeemable, convertible preferred stock dividend | $ | $ | ||||||
| Accretion of Series B redeemable, convertible preferred stock issuance costs | $ | $ | ||||||
| Accretion of Series C redeemable, convertible preferred stock dividend | $ | $ | ||||||
| Accretion of Series C redeemable, convertible preferred stock issuance costs | $ | $ | ||||||
| Exercise of warrants through debt principal conversion | $ | $ | ||||||
| Conversion of preferred stock into common stock | $ | $ | ||||||
| Conversion of amended 2017 convertible notes | $ | $ | ||||||
| Reclassification of derivative warrant liability into additional paid-in capital | $ | $ | ||||||
| Fair value of warrants issued to placement agent in relation to the Convertible debentures | $ | $ | ||||||
| Fair value of warrants for common stock issued for services | $ | $ | ||||||
| Offering costs included in accounts payable and accrued expenses | $ | $ | ||||||
See notes to unaudited condensed consolidated financial statements.
5
Bluejay Diagnostics, Inc.
Notes to the Condensed Consolidated Financial Statements
(Unaudited)
1. NATURE OF OPERATIONS AND BASIS OF PRESENTATION
Business
Bluejay Diagnostics, Inc. (the “Company”) commenced its activities on March 20, 2015 incorporated under the laws of the State of Delaware. The Company is a mission-driven in-vitro diagnostic company that aims to develop and market minimally-invasive Point-of-Care (“POC”) diagnostics tests and devices that provide patients and providers with access to affordable and timely healthcare. The Company’s focus is on the infectious disease, inflammation, and oncology markets.
The Company is pursuing biomarker detection of Sepsis, Cancer and other diseases, utilizing the Symphony technology platform and Symphony IL – 6 test licensed from Toray Industries, Inc. of Japan (see Note 3). The Company is also developing biomarkers for detection of other diseases such as Cardiac Ishcemia and Congestive Heart Failure.
The Company’s ALLEREYE diagnostic test (“ALLEREYE”) is a POC device that offers healthcare providers a cost effective, reliable, easy to use solution for diagnosis of Allergic Conjunctivitis. ALLEREYE received clearance by the U.S. Food and Drug Administration (the “FDA”) in October 2017.
On June 4, 2021, the Company created Bluejay Spinco, LLC, (“SpinCo”) a wholly owned subsidiary of the Company, for purposes of further development of ALLEREYE. The Company transferred assets and liabilities related to ALLEREY to SpinCo in accordance with the Contribution and Assumption Agreement. The assets and liabilities were transferred from the Company to SpinCo at their carrying value. The Company is responsible for the operational activities of SpinCo and bears all costs necessary to operate SpinCo. The Company’s CEO is also the CEO of SpinCo and oversees the business strategy and operations of SpinCo.
Initial Public Offering
The Company completed its initial public offering (“IPO”) on November 10, 2021 (“IPO Date”), whereby it sold 2,160,000 Units. Each Unit was sold at a price of $10.00. The gross proceeds from the IPO were approximately $21.6 million and were offset by $2.8 million in offering costs (see note 10).
Risks and Uncertainties
The Company is subject to a number of risks similar to other companies in its industries, including rapid technological change, competition from larger pharmaceutical and biotechnology companies and dependence on key personnel.
The extent of the impact of the COVID-19 pandemic on the Company’s business continues to be highly uncertain and difficult to predict, as the responses that the Company, other businesses and governments are taking continue to evolve. Furthermore, capital markets and economies worldwide have also been negatively impacted by the COVID-19 pandemic, and it is possible that it could cause a lasting national and/or global economic recession. Policymakers around the globe have responded with fiscal policy actions to support the healthcare industry and economy as a whole.
To date, the Company has experienced significant changes in the business as a result of the COVID-19 pandemic. The impact has delayed the Company’s ability to generate revenue as result of the diversification of potential customer budgets towards the COVID-19 pandemic. The extent to which the COVID-19 pandemic may in the future materially impact the Company’s financial condition, liquidity or results of operations is uncertain.
Stock Split
6
Liquidity
Since its inception, the Company has
devoted substantially all of its efforts to business planning, marketing and business development, research and development, and raising
capital. The income potential of the Company’s business and market are unproven. Successful transition to attaining profitable operations
is dependent upon achieving a level of revenues adequate to support the Company’s cost structure. As of September 30, 2021, the
Company had $
The Company believes it has sufficient
cash to meet its funding requirements for at least the next 12 months. However, the Company has experienced net losses and negative cash
flows from operating activities since its inception and has an accumulated deficit of $
Basis of Presentation
The accompanying unaudited condensed consolidated financial statements of the Company have been prepared in conformity with generally accepted accounting principles in the United States (“US GAAP”) consistent with those applied in, and should be read in conjunction with, the Company’s audited financial statements and related footnotes for the year ended December 31, 2020 included in the Company’s Form S-1 Registration Statement filed with the SEC on October 4, 2021. The unaudited condensed consolidated financial statements reflect all adjustments, which include only normal recurring adjustments, necessary for the fair presentation of the Company’s financial position as of September 30, 2021, its results of operations and cash flows for the three and nine months ended September 30, 2021 and 2020, in accordance with US GAAP. The unaudited condensed consolidated financial statements do not include all of the information and footnotes required by US GAAP for complete financial statements, as allowed by the relevant U.S. Securities and Exchange Commission (“SEC”) rules and regulations; however, the Company believes that its disclosures are adequate to ensure that the information presented is not misleading.
The results for the three and nine months ended September 30, 2021 are not necessarily indicative of the results that may be expected for the full fiscal year ending December 31, 2021, or any other interim period within this fiscal year.
All intercompany balances and transactions have been eliminated in consolidation.
| 2. | SIGNIFICANT ACCOUNTING POLICIES |
During the nine months ended September 30, 2021, there were no changes to the significant accounting policies as described in the 2020 Audited Financial Statements.
Use of estimates
The preparation of the Company’s condensed consolidated financial statements and related disclosures in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, and disclosures of contingent liabilities at the date of the condensed consolidated financial statements and the reported amounts of revenue and expenses during the reporting period. Significant estimates include, but are not limited to stock-based compensation expense, research and development accruals, fair value of common stock and fair value of stock warrants. Management evaluates its estimates on an ongoing basis. Although estimates are based on the Company’s historical experience, knowledge of current events and actions it may undertake in the future, actual results may materially differ from these estimates and assumptions.
Derivative instruments
The Company generally does not use derivative instruments to hedge exposures to cash flow or market risks; however, certain warrants to purchase preferred stock that do not meet the requirements for classification as equity are classified as liabilities. In such instances, net-cash settlement is assumed for financial reporting purposes, even when the terms of the underlying contracts do not provide for a net -cash settlement. Such financial instruments are initially recorded at fair value with subsequent changes in value charged (credited) to operations each reporting period. If these instruments subsequently meet the requirements for classification as equity, the Company reclassifies the then fair value to equity.
The Company values its outstanding warrants using the Black-Scholes option pricing model.
On June 1, 2021, the Series B Warrants were amended to become exercisable into common stock. As a result, the Series B Warrants met the requirements for classification as equity, and were reclassified to additional paid-in capital (see Note 7). The Series B Warrants were remeasured at fair value immediately prior to the reclassification.
7
The fair value of the outstanding Series B redeemable preferred stock warrants (see Note 7) at June 1, 2021 and December 31, 2020 was based on the assumptions as follows:
| June 1, | December 31, | |||
| 2021 | 2020 | |||
| Risk-free interest rate | ||||
| Dividend rate | ||||
| Volatility | ||||
| Expected life (in years) |
Stock-based compensation
Share-based compensation expense for all share-based payment awards made to employees, directors and non-employees is measured based on the grant-date fair value of the award. Share-based compensation expense for awards granted to non-employees is determined using the fair value of the consideration received or the fair value of the equity instruments issued, whichever is more reliably measured.
The Company uses the Black-Scholes option pricing model to determine the fair value of options granted. The Company recognizes the compensation cost of share-based awards on a straight-line basis over the requisite service period. For stock awards for which vesting is subject to performance – based milestones, the expense is recorded over the implied service period after the point when the achievement of the milestone is probable, or the performance condition has been achieved.
The determination of the fair value of share-based payment awards utilizing the Black-Scholes model is affected by the stock price and a number of assumptions, including expected volatility, expected life, risk-free interest rate and expected dividends. The Company does not have a history of market prices of its common stock, and as such, volatility is estimated using historical volatilities of similar public entities. The expected life of the awards is estimated based on the simplified method for grants to employees, and is based on the contractual term for non -employee awards. The risk-free interest rate assumption is based on observed interest rates appropriate for the terms of the awards. The dividend yield assumption is based on history and expectation of paying no dividends.
The Company recognizes forfeitures related to employee share-based payments when they occur. Forfeited options are recorded as a reduction to stock compensation expense.
Research and development expenses
Costs incurred for research and development are expensed as incurred. Research and development expenses primarily consist of salaries and related expenses for personnel, outside consulting services and sponsored research and the costs of materials and supplies used.
Redeemable Convertible Preferred Stock
The Company has classified redeemable, convertible preferred stock (“Preferred Stock”) as temporary equity in the accompanying condensed consolidated balance sheet at December 31, 2020 due to terms that allow for redemption of the shares upon certain events that are outside of the Company’s control. On June 1, 2021, the Company’s outstanding Preferred Stock was converted into common stock (see Note 8).
Segment Reporting
Management has determined that the Company has one operating segment, which is consistent with the Company structure and how it manages the business. As of September 30, 2021 and December 31, 2020, all of the Company’s assets were located in the United States.
Net Loss per Share
Basic net loss per share is computed by dividing the net loss by the weighted-average number of shares of common stock outstanding for the period, without consideration for potentially dilutive securities. Diluted net loss per share is computed by dividing the net loss by the weighted average number of shares of common stock and dilutive common stock equivalents outstanding for the period determined using the treasury stock and if-converted methods. Dilutive common stock equivalents are comprised of convertible preferred stock, convertible notes, options outstanding under the Company’s stock option plan and warrants. For all periods presented, there is no difference in the number of shares used to calculate basic and diluted shares outstanding as inclusion of the potentially dilutive securities would be antidilutive.
8
Potentially dilutive securities not included in the calculation of diluted net loss per share because to do so would be anti -dilutive are as follows (in common stock equivalent shares):
| September 30, | ||||||||
| 2021 | 2020 | |||||||
| Redeemable, convertible preferred stock | ||||||||
| Options to purchase common stock | ||||||||
| Warrants for common stock | ||||||||
| Warrants for Series B redeemable, convertible preferred stock | ||||||||
| Convertible debentures | ||||||||
Newly Adopted Accounting Standards
In August 2020, the FASB issued ASU 2020-06, Debt – Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging – Contracts in Entity’s Own Equity (Subtopic 815-40) Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity. This guidance changes how entities account for convertible instruments and contracts in an entity’s own equity and simplifies the accounting for convertible instruments by removing certain separation models for convertible instruments. This guidance also modifies the guidance on diluted earnings per share calculations. This new guidance is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2023. Early adoption is permitted, but no earlier than fiscal years beginning after December 15, 2020, including interim periods within those fiscal years. The Company elected to early adopt this guidance in the first quarter of 2021. The adoption of this standard had no material impact on the Company’s consolidated financial statements.
Recently Issued Accounting Standards
In May 2021, the FASB issued ASU 2021-04 Earnings Per Share (Topic 260), Debt—Modifications and Extinguishments (Subtopic 470-50), Compensation—Stock Compensation (Topic 718), and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Issuer’s Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options (a consensus of the FASB Emerging Issues Task Force). The amendments in this update are effective for all entities for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years. Early application is permitted, including in an interim period as of the beginning of the fiscal year that includes that interim period. The Company is currently evaluating the adoption date of this ASU and the impact, if any, adoption will have on its financial position and results of operations.
| 3. | BUSINESS AGREEMENTS |
License and Development Agreement with Naval Medical Research Center
On March 7, 2019, the Company entered
into a cooperative research and development agreement (“CRAD Agreement”) with Naval Medical Research Center (“NMRC”).
The objective of the agreement is for the development of lateral flow rapid test for sensitive and accurate diagnosis of various tick-borne
diseases including Lyme disease. The CRAD Agreement grants the Company a non-exclusive, royalty-free, non-commercial research use license
to any innovation made by NMRC occurring under the CRADA Agreement in performance of the objective. No payments were made in connection
with the CRADA Agreement during the nine-month periods ended September 30, 2021 and 2020. The remaining commitment under the CRADA Agreement
is $
License and Supply Agreement with Toray
On October 6, 2020, the Company entered
into a license and supply agreement (“Toray Agreement”) with Toray Industries, Inc. (“Toray”). Under the Toray
Agreement, the Company received the exclusive license to make and distribute the protein detection chips that has a function of automatic
stepwise feeding of reagent (“Toray Chips”) outside of Japan. In exchange for the license, the Company committed to make two
payments of $
| 4. | FAIR VALUE MEASUREMENTS |
Liabilities measured at fair value on a recurring basis at December 31, 2020 are summarized in the table below.
| December 31, 2020 | ||||||||||||||||
| Level 1 | Level 2 | Level 3 | Total | |||||||||||||
| Liabilities | ||||||||||||||||
| Derivative warrant liability | $ | $ | $ | $ | ||||||||||||
| $ | $ | $ | $ | |||||||||||||
There were no liabilities measured at fair value at September 30, 2021.
9
The table below presents the changes in Level 3 liabilities measured at fair value on a recurring basis during the nine months ended September 30, 2021.
| Warrant Liability | ||||
| Balance at December 31, 2020 | $ | |||
| Issuance of Series B warrants | ||||
| Unrealized gain | ( | ) | ||
| Fair value of Series B warrants converted into warrants for common stock | ( | ) | ||
| Balance at September 30, 2021 | $ | |||
Unrealized gain (loss) on revaluation of derivative warrant liability is included in derivative warrant liability gain (loss) in the condensed consolidated statements of operations.
There were no assets measured at fair value on a recurring basis, nor were there assets or liabilities measured at fair value on a non-recurring basis at September 30, 2021 or December 31, 2020.
| 5. | NOTES PAYABLE |
2017 Notes Payable
In 2017, the Company entered into multiple
Unit Purchase Agreements. In connection with this financing (the “Financing”), the Company issued
Certain Notes with aggregate principal
amount of $
The allocation of the gross proceeds
from the Financing resulted in recording a premium on the Notes of $
In connection with the Financing, the
Company paid $
On February 17, 2021, the Company
repaid in cash $
On May 26, 2021, the remaining Notes
were amended and restated (the “Amended Notes”). The Amended Notes accrue no interest and are due in May 2023. The Amended
Notes are automatically convertible into a number of shares of common stock at the conversion rate of $
10
The Amended Notes principal
automatically converted on June 8, 2021 into
2020 Subordinated Promissory Notes
On October 22, 2020, the Company issued $
In conjunction with the issuance of the Subordinated
Notes, the Company issued to each noteholder warrants to purchase shares of the Company’s common stock (“Common Stock Warrants”)
totaling
The Common Stock Warrants were accounted for as equity
under ASC 815 – Derivatives and Hedging. The proceeds from the issuance of the Subordinated Notes were allocated between
the Subordinated Notes and the Common Stock Warrants based on their relative fair values, with $
The allocation of the proceeds to the
Common Stock Warrants resulted in a discount to the Subordinated Notes of $
On June 7, 2021, the holders of $
| 6. | CONVERTIBLE DEBENTURES |
On June 7, 2021, the Company entered
into a Securities Purchase Agreement with Sabby, under which the Company committed to sell, and Sabby agreed to purchase, an aggregate
of $
On June 8, 2021, the Company issued
a total of $
For the three and nine months ended
September 30, 2021, interest expense on the Convertible Debentures was $
The Company incurred $
11
Under the terms of the service agreement,
the placement agent was entitled to warrants for the Company’s shares as compensation for its services in relation to the Sabby
Investment. In August 2021, the Company issued the total of
| 7. | WARRANTS |
In March 2021, the Company granted
to a financial advisor warrants to purchase
The terms of the advisory services agreement also provide
for an incentive bonus of $
The following assumptions were used in the Black-Scholes option pricing model to estimate the fair value of the Common Stock Warrants granted during the three months ended September 30, 2021:
| Risk-free interest rate | ||||
| Dividend rate | ||||
| Volatility | ||||
| Expected life (in years) |
The Series B Warrants issued in conjunction
with the Series B (see Note 8) were accounted for as a derivative liability under ASC 480 – Distinguishing Liabilities from Equity.
The fair value of Series B Warrants at the issuance date in 2020 and 2019 was determined to be $
On June 1, 2021, as a result of the
conversion of Series B into common stock (see Note 8), the outstanding 731 Series B Warrants were amended to become exercisable into
The following table summarizes information with regard to warrants outstanding at September 30, 2021:
| Shares | Exercisable for | Weighted Average Exercise Price | Weighted |
|||||||||||
| Common Stock Warrants | Common Stock | $ | ||||||||||||
| 8. | STOCKHOLDERS’ EQUITY |
Preferred Stock
The Company’s Certificate of
Incorporation, as amended on June 7, 2021, provided authorization for issuance of up to
Prior to June 1, 2021, the Company had outstanding Series A redeemable, convertible preferred stock (“Series A”), Series B redeemable, convertible preferred stock (“Series B”), Series C redeemable, convertible preferred stock (“Series C”), collectively referred to as “Preferred Stock”.
In connection with the Financing (see
Note 5), the Company issued
12
On April 5, 2019, the Company
entered into Subscription Agreements for the issuance of Series B (the “Series B Financing”). In connection with the
Series B Financing, the Company issued
In connection with the Series B Financing, in
2019 the Company entered into an Amended Subscription Agreement with an investor to issue additional Series B and warrants for committed
proceeds up to $
The remaining $
The Series B were subject to accretion to the
redemption value through December 31, 2024, the redemption date. Accretion of the Series B to redemption value, including the accretion
of dividends and issuance costs, was $
On November 19, 2020, the Company entered
into a Subscription Agreement for the issuance of Series C (the “Series C Financing”) with Toray. In connection with the Series
C Financing, the Company issued
The Series C were being accreted to the redemption
value through December 31, 2021, the redemption date. Accretion of the Series C to redemption value, including the accretion of dividends
and issuance costs, was $
On June 1, 2021, in connection with the debt financing
by Sabby (see Note 6), the Company’s Series A were converted into
The Series A ranked senior to Series B and Series C. Series B was pari passu with the Series C. Significant terms of the Series A, Series B and Series C (collectively, “Preferred Stock”) were as follows:
Voting
The holder of each share of Preferred Stock has the right to vote for each share of common stock into which such Preferred Stock could convert. Except as otherwise provided, the holders of Preferred Stock and Common Stock shall vote together as a single class.
Dividends
The holders of Preferred Stock shall be entitled
to receive dividends at a rate per annum of
Liquidation Preference
In the event of any liquidation, dissolution or winding up of the Company, the holders of Series A shall be entitled to be paid out of the assets of the Company, after all creditors of the Company have been paid, before any payments shall be made to the holders of Series B, Series C and common stock, in the amount of the Original Offering Price per share, plus all accrued but unpaid dividends thereon. If insufficient assets and funds are available to permit payment to the Series A holders, then all available assets and funds shall be distributed to the Series A holders on a pro rata basis. All dividends accrued and unpaid to the date of such distribution shall be paid out of the assets of the Company before any distribution is made to the holders of any junior stock of the Company.
In the event of any liquidation, dissolution or winding up of the Company, the holders of Series B and Series C, which are pari passu stocks, shall be entitled to be paid out of the assets of the Company before any payments shall be made to the holders of the common stock, in the amount of the Original Offering Price per share, plus all accrued but unpaid dividends thereon. If insufficient assets and funds are available to permit payment to the Series B and Series C holders, then all available assets and funds shall be distributed to the Series B and Series C holders on a pro rata basis. All dividends accrued and unpaid to the date of such distribution shall be paid out of the assets of the Company before any distribution is made to the holders of any junior stock of the Company.
Conversion
Each share of Series A, Series B and Series C is entitled to
convert into
13
Redemption
If the Company has not had an Initial Public Offering, or has not been acquired by December 31, 2024, the Company will be required, upon request of the holders of at least two thirds of the outstanding shares, to redeem the outstanding Preferred Stock at the greater of (i) Original Offering Price, plus accrued dividends, or (ii) the fair market value as determined by an appraiser selected by Company who is reasonably acceptable to the holders of a majority of the outstanding Preferred Stock and paid for by the Company.
On June 7, 2021, the Company filed a certificate
of designation of preferences, rights, and limitations with the state of Delaware for up to
Voting
The Series D shall have no voting rights.
Dividends
The holders shall be entitled to receive cumulative
quarterly dividends at a rate of $
Liquidation Preference
In the event of any liquidation, dissolution or
winding up of the Company, the holders of Series D shall be entitled to be paid out of the assets of the Company, after all creditors
of the Company have been paid, before any payments shall be made to the holders of Common Stock, in the amount equal to the Stated Value
of $
Conversion
Each share of Series D shall be convertible into
Stock Incentive Plans
In 2018,
On July 6, 2021, the Company’s board of directors and stockholders approved and adopted the Bluejay Diagnostics, Inc. 2021 Stock Plan (the “2021 Plan”). A total of 1,960,000 shares of common stock were approved to be initially reserved for issuance under the 2021 Stock Plan. The Company can continue to issue shares under the 2018 Plan. At September 30, 2021, there were 1,770,000 and 253,614 shares available for grants under the 2021 and 2018 Plans, respectively.
The Company calculated the grant-date fair value of share-based awards granted during the nine-month period ended September 30, 2021 using the Black-Scholes model with the following assumptions:
| Risk-free interest rate | ||||
| Expected dividend yield | ||||
| Volatility factor | ||||
| Expected life of option (in years) |
The following is a summary of stock option activity for the nine months ended September 30, 2021:
| Number of Stock Options | Weighted Average Exercise Price Per Share | Weighted Average Remaining Contractual Life in Years | Aggregate Intrinsic Value | |||||||||||||
| Outstanding at December 31, 2020 | $ | $ | ||||||||||||||
| Granted | ||||||||||||||||
| Exercised | ( | ) | ||||||||||||||
| Cancelled / forfeited | ( | ) | ||||||||||||||
| Outstanding at September 30, 2021 | $ | $ | ||||||||||||||
| Exercisable at September 30, 2021 | $ | $ | ||||||||||||||
The weighted average grant date fair value of options granted during
the nine months ended September 30, 2021 and 2020 was $
14
For the three and nine months ended September
30, 2021, the Company recorded stock-based compensation expense of $
At September 30, 2021, there was approximately $
| 9. | RELATED PARTY TRANSACTIONS |
LMBRI has board members in common with
the Company. Funds were advanced to the Company by LMBRI for operational and Food and Drug Administration (“FDA”) pre-submission
funding purposes since inception. Amounts payable to LMBRI from the Company at September 30, 2021 and December 31, 2020 were $
The Company and LMBRI have entered
into an Expense Sharing Agreement, whereby the Company will reimburse LMBRI monthly for certain shared expenses including insurance, rent,
salaries, telephone, and other miscellaneous expenses. The Company is billed $
The table below summarizes the amounts incurred and paid to LMBRI under the Expense Sharing Agreement during the three and nine months ended September 30, 2021 and 2020.
| Three Months Ended September 30, |
Nine Months Ended September 30, |
|||||||||||||||
| 2021 | 2020 | 2021 | 2020 | |||||||||||||
| Expenses from LMBRI | $ | $ | $ | – | $ | |||||||||||
| Payments to LMBRI | $ | $ | $ | $ | ||||||||||||
| 10. | SUBSEQUENT EVENTS |
Except as noted below, there were no subsequent events that were not disclosed in notes 1 and 8 to the condensed consolidated financial statements.
On October 21, 2021 the company filed
its Amended and Restated certificate of incorporation to authorize the issuance of
The Company completed its initial public offering (“IPO”) on November 10, 2021 (“IPO Date”), whereby it sold 2,160,000 Units, each Unit consisting of one share of the Company’s common stock, one warrant to purchase one share of common stock at an exercise price of $7.00 per share (“Class A Warrant”), and one warrant to purchase one share of common stock at an exercise price of $10.00 (“Class B Warrant”) (collectively, a “Unit”). Each Unit was sold at a price of $10.00. Each warrant contained within the Units is exercisable until the fifth anniversary of the IPO date, however, holders of Class B Warrants may exercise such warrants on a “cashless” basis after the earlier of (i) 10 trading days from closing date of the offering or (ii) the time when $10.0 million of volume is traded in our common stock, if the volume weighted average price of the Company’s common stock on any trading day on or after the closing date of the offering fails to exceed the exercise price of the Class B Warrant (subject to adjustment as described in the warrant agreement). The gross proceeds from the IPO were approximately $21.6 million and were offset by $2.8 million in offering costs (see note 10).
In connection with the IPO, all of the
Company’s outstanding Convertible Debentures (see Note 6) automatically converted into
Pursuant to the underwriting agreement, to cover
over-allotments in connection with the IPO,
As described in more detail in Note 1,
In connection with the IPO, on November
10, 2021, all of the Company’s outstanding Convertible Debentures automatically converted into
Between November 10, 2021 and November
26, 2021, the holders of all the
Between November 11, 2021 and December 1, 2021,
the holders of
In November 2021, the terms of the Common Stock Warrants issued to the Subordinated Notes noteholders were amended to provide for cashless exercise (see Note 5).
15
ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
You should read the following discussion and analysis of our financial condition and results of operations in conjunction with the unaudited condensed consolidated financial statements and the related notes appearing elsewhere in this Form 10-Q. This discussion contains forward-looking statements reflecting our current expectations that involve risks and uncertainties. Actual results and the timing of events could differ materially from those discussed in our forward-looking statements as a result of many factors, including those set forth under “Risk Factors” and elsewhere in this Form 10-Q.
Overview
We are a late-stage pre-revenue company focused on improving patient outcomes through a more cost efficient, rapid, near patient product for triage, diagnosis and monitoring of disease progression. We believe there is a market need for an on-site and rapid diagnostic system that can be employed for testing and monitoring. Our diagnostic system, which we refer to as “Symphony,” is an exclusively licensed, patented, low-cost, system that consists of a small footprint instrument and single-use indication specific test cartridges, that we believe, if cleared, authorized, or approved by the U.S. Food and Drug Administration (“FDA”), can provide a solution to this market need with rapid and with laboratory quality results in approximately 24 minutes, in the clinic, Intensive Care Unit (“ICU”), Emergency Room (“ER”) and in other hospital and clinical setting settings where a rapid and reliable results are required. Currently, testing is generally performed in a laboratory, and the transportation and logistics of transporting the samples to the lab and obtaining the result takes between 8-48 hours. Our platform is a sample-to-result system that has been shown in a clinical study to provide results in 24 minutes. Our business model is to generate revenue from the sale of the table-top Symphony instrument, and from the sale of single-use indication specific cartridges that are used by the Symphony instrument for the diagnostic test. Once the test material (generally a small volume blood sample) is transferred to a single-use indication specific Symphony cartridge, no additional sample preparation or pre-processing is required.
Since inception, we have incurred net losses from operations each year and we expect to continue to incur losses for the foreseeable future. We incurred net losses of approximately $1.2 million, $128,000, $2 million and $614,000 for the three-month and nine-month periods ended September 30, 2021 and 2020, respectively. We had negative cash flow from operating activities of approximately $1.8 million and $354,000 for the nine-month periods ended September 30, 2021 and 2020, respectively, and had an accumulated deficit of approximately $6.2 million as of September 30, 2021.
Results of Operations
Comparison of the Three-Month Periods Ended September 30, 2021 and 2020
The following table sets forth our results of operations for the three-month periods ended September 30, 2021 and 2020:
| Three Months Ended September 30, | ||||||||
| 2021 | 2020 | |||||||
| Operating expenses: | ||||||||
| Research and development | $ | 442,527 | $ | 2,723 | ||||
| General and administrative | 445,050 | 131,094 | ||||||
| Marketing and business development | 70,411 | 14,352 | ||||||
| Total operating expenses | 957,988 | 148,169 | ||||||
| Operating loss | (957,988 | ) | (148,169 | ) | ||||
| Other income (expense) | ||||||||
| Derivative warrant liability gain (loss) | - | 4,344 | ||||||
| Interest (expense) income, net of amortization of premium | (237,429 | ) | 15,833 | |||||
| Other income | 2,036 | 4 | ||||||
| Total other income (expense), net | (235,393 | ) | 20,181 | |||||
| Net loss | $ | (1,193,381 | ) | $ | (127,988 | ) | ||
16
Research and Development
Research and development expenses increased approximately $440,000, or 16,151%, for the three-month period ended September 30, 2021, as compared to the same period of 2020. The increase was primarily due to expenses incurred totaling approximately $296,000 in connection with the clinical trials and manufacturing costs related to the Symphony analyzers. Employee compensation and benefits increased by approximately $128,000. Research and development expenses were significantly lower in 2020 as a result of the COVID-19 pandemic-related slowdown.
General and Administrative
General and administrative expenses increased approximately $314,000, or 239%, for the three-month period ended September 30, 2021, as compared to the same period of 2020. The increase was attributable to increased operating expenses related to the company’s transition from a private company to a public company, including the addition of accounting, legal and audit related expenses totaling approximately $127,000. In addition, expenses related to employee compensation and benefits increased by approximately $168,000 due to an increase in general and administrative headcount.
Marketing and Business Development
Marketing and business development expenses increased approximately $56,000, or 391%, for the three-month period ended September 30, 2021, as compared to the same period of 2020. The increase was primarily attributable to increased employee compensation and benefits of approximately $54,000 to expand the development and commercialization of our Symphony platform.
Interest (Expense) Income, Net of Amortization of Premium
Interest expense increased by approximately $253,000, or 1,600%, for the three-month period ended September 30, 2021 as compared to the same period of 2020. The increase was primarily related to the stated interest and amortization of discount on the Convertible Debentures issued in June and August 2021 of approximately $163,000 and $65,000, respectively. The interest expense incurred during the three-month period ended September 30, 2020, included $13,334 interest expenses by offset by $29,167 amortization of premium on the notes payable issued in 2017.
Comparison of the Nine-Month Periods Ended September 30, 2021 and 2020
The following table sets forth our results of operations for the nine months ended September 30, 2021 and 2020:
| Nine Months Ended September 30, | ||||||||
| 2021 | 2020 | |||||||
| Operating expenses: | ||||||||
| Research and development | $ | 692,702 | $ | 108,192 | ||||
| General and administrative | 974,791 | 452,846 | ||||||
| Marketing and business development | 189,765 | 53,574 | ||||||
| Total operating expenses | 1,857,258 | 614,612 | ||||||
| Operating loss | (1,857,258 | ) | (614,612 | ) | ||||
| Other income (expense) | ||||||||
| Derivative warrant liability gain (loss) | 9,676 | (45,323 | ) | |||||
| Interest income (expense), net of amortization of premium | (269,545 | ) | 40,443 | |||||
| Grant income | 75,000 | - | ||||||
| Other income | 14,325 | 5,232 | ||||||
| Total other income (expense), net | (170,544 | ) | 352 | |||||
| Net loss | $ | (2,027,802 | ) | $ | (614,260 | ) | ||
Research and Development
Research and development expenses increased approximately $585,000, or 540%, for the nine-month period ended September 30, 2021, as compared to the same period of 2020. The increase was primarily due to expenses incurred totaling approximately $441,000 in connection with the clinical trials and manufacturing costs related to the Symphony analyzers. Research and development expenses were significantly lower in 2020 as a result of the COVID-19 pandemic-related slowdown.
17
General and Administrative
General and administrative expenses increased approximately $522,000, or 115%, for the nine-month period ended September 30, 2021, as compared to the same period of 2020. The increase was primarily attributable to increased operating expenses related to the company’s transition from a private to public company, including the addition of accounting, legal and audit related expenses totaling approximately $334,000. In addition, expenses related to employee compensation and benefits increased by approximately $58,000 due to an increase in general and administrative headcount. Expense for expiring inventory of approximately $85,000 was recorded in the second quarter of 2021, versus no such expense recorded during the nine months ended September 30, 2020.
Marketing and Business Development
Marketing and business development expenses increased approximately $136,000, or 254%, for the nine-month period ended September 30, 2021, as compared to the same period of 2020. The increase was primarily attributable to increased marketing and business development expenses of approximately $140,000 paid to consultants and employees to expand the development and commercialization of our Symphony platform.
Derivative Warrant Liability Gain (Loss)
Derivative warrant liability gain (loss) increased by approximately $55,000, or 121%, for the nine-month period ended September 30, 2021 as compared to the same period of 2020, resulting from the revaluation of the Series B Warrants accounted for as liability until their reclassification into equity in June 2021.
Interest Income (Expense), Net of Amortization of Premium
Interest income (expense) decreased by approximately $310,000, or 766%, for the nine-month period ended September 30, 2021 as compared to the same period of 2020. The decrease was primarily related to the amortization of discount and accrued interest on the Convertible Debentures issued in June and August 2021 of approximately $204,000 and $89,000, respectively. The interest expense incurred during the nine-month period ended September 30, 2020, included $47,059 interest expenses offset by $87,502 amortization of premium on the notes payable issued in 2017.
Grant Income
Grant income increased by approximately $75,000, or 100%, for the nine-month period ended September 30, 2021 as compared to the same period of 2020. The increase was due to a $75,000 grant received from Massachusetts Growth Capital Corporation
Liquidity and Capital Commitments
Liquidity
We have funded our operations to date primarily with net proceeds from sales of our common and preferred stock and issuance of convertible notes. As of September 30, 2021, the Company had $2.3 million in unrestricted cash and cash equivalents. Additionally, in November 2021, the Company issued 2,160,000 Units in connection with the IPO, generating gross proceeds of $21.6 million.
In 2017, we issued 106 units, at a purchase price of $20,000 per unit, with each unit consisted of 100 shares of Series A redeemable, convertible preferred stock (“Series A”) at a purchase price of $100 per share and $10,000 in notes payable (the “Notes”). Gross proceeds from the financing were $2,120,000, less $183,194 in issuance costs. All Series A and related notes were converted to common stock and retired on June 1, 2021.
On April 5, 2019, we issued 4,455 shares of Series B redeemable, preferred stock (“Series B”) at a purchase price of $361.50 per share. Gross proceeds from the Series B financing were approximately $1.61 million. We also issued 622 Series B warrants in connection with the Series B financing. Through the rest of 2019 we issued an additional 277 shares of Series B and 41 Series B warrants for gross proceeds of $100,000. In 2020, we issued 456 additional shares of Series B and 68 Series B warrants for gross proceeds of $50,000. The 731 warrants convertible into Series B were adjusted and restated to convert into 36,600 shares of common stock and following the split were convertible into 115,190 shares of common stock.
On October 22, 2020, we issued $154,000 of 8% subordinated promissory notes (“Subordinated Notes”) to related party shareholders, as well as warrants to purchase 1,154,000 (prior to the stock dividend) shares of common stock at $0.10 per share, exercisable in cash or through cancellation of the notes. All warrants were adjusted and restated to be convertible to common stock on June 1, 2021. On June 7, 2021 all notes were converted to common stock pursuant to related warrants or repaid (see below).
In November 2020, we issued 636 shares of Series C redeemable, convertible preferred stock (“Series C”) at a purchase price of $1,578.50 per share and received proceeds, net of issuance costs of approximately $995,000. All shares were converted to common stock in June 2021.
In 2020, we received loan proceeds of $116,000 from a Paycheck Protection Program loan (“PPP loan”). In November 2020, we received notice of forgiveness of $102,000 of principal of the PPP loan and, in February 2021, we received an adjustment which increased the forgiven balance by approximately $5,000 and repaid the $9,000 related to the unforgiven balance.
On June 1, 2021, our Series A with a stated value of approximately $1.1 million was converted into 530,000 (prior to the stock dividend) shares of common stock, our Series B preferred stock with a stated value of approximately $1.8 million was converted into 259,350 (prior to the stock dividend) shares of common stock, and our Series C preferred stock with a stated value of approximately $1.0 million was converted into 31,800 (prior to the stock dividend) shares of common stock. In addition, holders of our 2017 secured notes amended and restated their agreement such that the notes would automatically convert into 184,292 (prior to the stock dividend) shares of common stock upon the occurrence of a qualified financing (as defined in the notes) and certain warrants issued in connection with the issue of Series B preferred stock were amended and restated to be exercisable into common stock.
18
On June 7, 2021, certain holders of approximately $132,000 in principal of our convertible subordinated notes elected to convert their debt, inclusive of accrued interest, into 1,323,830 (prior to the stock dividend) shares of common stock and we repaid the remaining principal and interest of approximately $28,000 on the remaining notes.
Also on June 7, 2021, we:
| ● | declared a stock dividend which increased the number of shares of common stock outstanding from 3,329,272 to 10,477,880; |
| ● | adjusted the number of shares of common stock issuable upon exercise of the restated Series B warrants from 36,600 to 115,190; |
| ● | adjusted the number of shares of common stock issuable upon exercise of the remaining warrants issued with subordinated notes from 216,170 to 680,331; |
| ● | adjusted the number of shares issuable upon exercise of outstanding options under our 2018 equity incentive plan from 119,416 to 375,826 and the number of shares reserved for issue under future grants from 80,584 to 253,614; and |
| ● | approved an amendment to our certificate of incorporation to increase the number of authorized shares of common and preferred stock to 30 million and 5 million shares, respectively. |
On June 8, 2021, we entered into an agreement to issue a total of $4.5 million of 7.5% Senior Secured Convertible Debentures (the “Debentures”) to Sabby Volatility Master Fund, Ltd (“Sabby”), of which $3.0 million of the Debentures were issued at closing. The agreement provides for the purchase by Sabby of an additional $1.5 million of the Debentures after we file a registration statement for an initial public offering. The Debentures are convertible, at Sabby’s option, into our Series D Preferred Stock at a conversion price of $1,000 per share.
On August 4, 2021 we issued an additional $1.5 million in principal amount of the Debentures to Sabby.
On October 21, 2021 we filed its Amended and Restated certificate of incorporation to authorize the issuance of 105,000,000 shares, consisting of 100,000,000 shares of common stock and 5,000,000 shares of preferred stock. 4,500 share of Preferred Stock are designated as Series D Convertible Preferred Stock.
On November 10, 2021 (“IPO Date”), we completed our initial public offering (“IPO”) whereby we sold 2,160,000 Units, each Unit consisting of one share of common stock, one warrant to purchase one share of common stock at an exercise price of $7.00 per share (“Class A Warrant”), and one warrant to purchase one share of common stock at an exercise price of $10.00 (“Class B Warrant”) (collectively, a “Unit”). Each Unit was sold at a price of $10.00. Each warrant contained within the Units is exercisable until the fifth anniversary of the IPO date. The gross proceeds from the IPO were approximately $21.6 million. The offering costs related to the IPO were $2.8 million.
We estimate that our available cash resources will be sufficient to fund our operations for at least twelve months from the date of this report. We expect to continue to incur net losses for the foreseeable future and believes we will need to raise substantial additional capital to accomplish our business plan over the next several years. In order to finance continued business development, to generate sales, to invest in further research and development and to otherwise satisfy obligations as they mature, we may need to seek additional financing through the issuance of common stock, preferred stock, and convertible or non-convertible debt financing. Additional funding, however, may not be available to us on acceptable terms, or at all. If we are unable to access additional funds when needed, we will not be able to continue the development of our platform, our tests or we could be required to delay, scale back or eliminate some or all of our research and development programs and other operations. Any additional equity financing, if available to us, may not be available on favorable terms, will most likely be dilutive to our current stockholders, and debt financing, if available, may involve restrictive covenants. Any of these events could harm our business, financial condition and prospects.
Capital Commitments
We have entered into agreements with two contract manufacturing organizations (“CMO”) to manufacture protein detection chips for the Symphony product. Purchases made under these agreements are generally non-cancellable shortly after the CMOs acceptance of the purchase order, however, there were minimal non-cancellable commitments as of September 30, 2021 and December 31, 2020. In addition, as part of the Toray Agreement, following the first sale of protein detection chips, we will also make royalty payments to Toray equal to 15% of the net sales of the Toray Chips for the period that any underlying patents exist or for 5 years after the first sale. Following the first sale, we will pay a one-time minimum royalty of $60,000, which shall be creditable against any royalties owed to Toray in such calendar year. We will pay a minimum royalty of $100,000 in each year thereafter, which are creditable against any royalties owed to Toray in such calendar year. There were no sales of or revenues from the protein detection chips through September 30, 2021.
Summary Statement of Cash Flows
The following table sets forth the primary sources and uses of cash and cash equivalents for each of the periods presented.
| Nine Months Ended September 30, | ||||||||
| 2021 | 2020 | |||||||
| Cash proceeds provided by (used in): | ||||||||
| Operating activities | $ | (1,843,722 | ) | $ | (353,854 | ) | ||
| Investing activities | (6,214 | ) | - | |||||
| Financing activities | 3,267,713 | 330,611 | ||||||
| Net increase (decrease) in cash and cash equivalents | $ | 1,417,777 | $ | (23,243 | ) | |||
19
Net cash used in operating activities
Net cash used in operating activities was approximately $1.8 million for the nine-month period ended September 30, 2021. We had a net loss of approximately $2.03 million and a decrease in working capital of approximately $119,000, offset by non-cash depreciation expense of approximately $107,000, non-cash interest expense of approximately $165,000, and stock-based compensation expense of approximately $47,000. The change in working capital was primarily due to increased prepaid and other current assets of 390,000 offset by increased accrued and other current liabilities of 281,169.
Net cash used in operating activities was approximately $354,000 for the three-month period ended September 30, 2020. We had a net loss of approximately $614,000 and non-cash interest income of approximately $74,000 related to amortization of discount and premium on notes payable, offset by non-cash depreciation expense of approximately $111,000, non-cash loss on revaluation of derivative warrant liability of approximately $74,000 which is required each reporting period, and a decrease in working capital of approximately $173,000. The change in working capital was primarily due to increases in accounts payable and related party payables offset by an $85,000 increase in inventory received in a settlement.
Net cash provided by financing activities
Net cash provided by financing activities was approximately $3.3 million for the nine months ended September 30, 2021. The proceeds were primarily the result of the receipt of $4.5 million from the issuance of convertible debentures in June and August 2021, offset by payments of issuance costs of $563,000, deferred offering costs of approximately $393,000, and payments of our outstanding notes payable of approximately $290,000.
Net cash provided by financing activities was approximately $331,000 for the nine months ended September 30, 2020. The proceeds were primarily attributable to $116,000 from our PPP loan, approximately $61,000 we received from issuance of Series B redeemable, convertible preferred stock, net of issuance costs, and approximately $154,000 received for subscriptions to the 2020 promissory notes.
Recently Adopted Accounting Standards
In August 2020, FASB issued ASU 2020-06, Debt — Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging — Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity, which, among other things, provides guidance on how to account for contracts on an entity’s own equity. This ASU eliminates the beneficial conversion and cash conversion accounting models for convertible instruments. It also amends the accounting for certain contracts in an entity’s own equity that are currently accounted for as derivatives because of specific settlement provisions. In addition, this ASU modifies how particular convertible instruments and certain contracts that may be settled in cash or shares impact the diluted EPS computation. The amendments in this ASU are effective for public companies for fiscal years beginning on or after December 15, 2023, including interim periods within those fiscal years. Early adoption is permitted, but no earlier than fiscal years beginning after December 15, 2020. The Company elected to adopt early this guidance in the first quarter of 2021. The adoption of this standard had no material impact on the Company’s condensed consolidated financial statements.
Recently Issued Accounting Standards
In May 2021, the FASB issued ASU 2021-04 Earnings Per Share (Topic 260), Debt—Modifications and Extinguishments (Subtopic 470-50), Compensation—Stock Compensation (Topic 718), and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Issuer’s Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options (a consensus of the FASB Emerging Issues Task Force). The amendments in this update are effective for all entities for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years. Early application is permitted, including in an interim period as of the beginning of the fiscal year that includes that interim period. The Company is currently evaluating the adoption date of this ASU and the impact, if any, adoption will have on its financial position and results of operations.
Critical Accounting Policies and Estimates
Some of our critical accounting policies require us to make difficult, subjective or complex judgments or estimates. An accounting estimate is considered to be critical if it meets both of the following criteria: (i) the estimate requires assumptions about matters that are highly uncertain at the time the accounting estimate is made, and (ii) different estimates reasonably could have been used, or changes in the estimate that are reasonably likely to occur from period to period may have a material impact on the presentation of our financial condition, changes in financial condition or results of operations.
As an emerging growth company, we have elected to opt-in to the extended transition period for new or revised accounting standards. As a result, our condensed consolidated financial statements may not be comparable to those of companies that comply with public company effective dates.
20
Stock-based compensation
Our stock-based compensation expense for stock awards is estimated at the grant date based on the award’s fair value as determined by the consideration received or as calculated by the Black-Scholes option pricing model, whichever is more readily measurable. The Black-Scholes pricing model requires various highly judgmental assumptions including expected volatility and expected term. The expected volatility is based on the historical stock volatilities of several similar public companies over a period equal to the expected terms of the awards as we do not have a trading history to use the volatility of our own common stock. To estimate the expected term, we have opted to use the simplified method, which is the use of the midpoint of the vesting term and the contractual term. The Company recognizes the compensation cost of share-based awards on a straight-line basis over the requisite service period, however, for stock awards for which vesting is subject to performance – based milestones, the expense is recorded over the implied service period after the point when the achievement of the milestone is probable, or the performance condition has been achieved. If any of the assumptions used in the Black-Scholes pricing model changes significantly, stock-based compensation expense may differ materially in the future from that recorded in the current period
Emerging Growth Company and Smaller Reporting Company Status
We are an emerging growth company, as defined in the JOBS Act. Under the JOBS Act, emerging growth companies can delay adopting new or revised accounting standards issued subsequent to the enactment of the JOBS Act until such time as those standards apply to private companies. We elected to use this extended transition period for complying with new or revised accounting standards that have different effective dates for public and private companies until the earlier of the date that we (i) are no longer an emerging growth company or (ii) affirmatively and irrevocably opt out of the extended transition period provided in the JOBS Act. As a result, these condensed consolidated financial statements may not be comparable to companies that comply with the new or revised accounting pronouncements as of public company effective dates. We are using the extended transition period for any other new or revised accounting standards during the period in which we remain an emerging growth company.
We will remain an emerging growth company until the earliest of (i) the last day of our first fiscal year (a) following the fifth anniversary of the completion of this offering, (b) in which we have total annual gross revenues of at least $1.07 billion or (c) in which we are deemed to be a large accelerated filer, which means the market value of our common stock that is held by non-affiliates exceeds $700 million as of the prior June 30th and (ii) the date on which we have issued more than $1.0 billion in non-convertible debt securities during the prior three-year period.
We are also a “smaller reporting company,” meaning that the market value of our stock held by non-affiliates plus the proposed aggregate amount of gross proceeds to us as a result of this offering is less than $700.0 million and our annual revenue is less than $100 million during the most recently completed fiscal year. We may continue to be a smaller reporting company after this offering if either (i) the market value of our stock held by non-affiliates is less than $250 million or (ii) our annual revenue is less than $100 million during the most recently completed fiscal year and the market value of our stock held by non-affiliates is less than $700 million. If we are a smaller reporting company at the time we cease to be an emerging growth company, we may continue to rely on exemptions from certain disclosure requirements that are available to smaller reporting companies. Specifically, as a smaller reporting company we may choose to present only the two most recent fiscal years of audited financial statements in our Annual Reports on Form 10-K and, similar to emerging growth companies, smaller reporting companies have reduced disclosure obligations regarding executive compensation
21
JOBS Act Accounting Election
The recently enacted JOBS Act provides that an “emerging growth company” can take advantage of the extended transition period provided in Section 7(a)(2)(B) of the Securities Act of 1933, as amended, for complying with new or revised accounting standards. In other words, an “emerging growth company” can delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. We have irrevocably elected not to avail ourselves of this extended transition period and, as a result, we will adopt new or revised accounting standards on the relevant dates on which adoption of such standards is required for other public companies.
We have implemented all new accounting pronouncements that are in effect and may impact our financial statements and we do not believe that there are any other new accounting pronouncements that have been issued that might have a material impact on our financial position or results of operations.
Item 3. Quantitative and Qualitative Disclosures About Market Risk
We are a smaller reporting company as defined by Rule 12b-2 of the Exchange Act and are not required to provide the information required under this item.
Item 4. Controls and Procedures
Evaluation of Disclosure Controls and Procedures and Changes in Internal Control over Financial Reporting
Our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e)) are designed to ensure that information required to be disclosed by us in reports we file or submit under the Securities Exchange Act of 1934, as amended, is recorded, processed, summarized and reported within the appropriate time periods, and that such information is accumulated and communicated to the Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely discussions regarding required disclosure. We, under the supervisions of and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer, have evaluated the effectiveness of our disclosure controls and procedures. Based on that evaluation, our Chief Executive Officer and Chief Financial Officer concluded that the design and operation of our disclosure controls and procedures were effective as of September 30, 2021.
Due to a transition period established by SEC rules applicable to newly public companies, our management is not required to evaluate the effectiveness of our internal control over financial reporting until after the filing of our Annual Report on Form 10-K for the year ended December 31, 2021. As a result, this Quarterly Report on Form 10-Q does not address whether there have been any changes in our internal control over financial reporting.
22
PART II - OTHER INFORMATION
Item 1. Legal Proceedings
From time to time in the ordinary course of our business, we may be involved in legal proceedings, the outcomes of which may not be determinable. The results of litigation are inherently unpredictable. Any claims against us, whether meritorious or not, could be time consuming, result in costly litigation, require significant amounts of management time and result in diversion of significant resources. We are not able to estimate an aggregate amount or range of reasonably possible losses for those legal matters for which losses are not probable and estimable. We have insurance policies covering potential losses where such coverage is cost effective.
We are not at this time involved in any legal proceedings.
Item 1A. Risk Factors
For a discussion of potential risks or uncertainties, see “Risk Factors” in the Company’s registration statement on Form S-1, as amended (File No. 333-260029), on file with the SEC. Except as set forth below, there have been no material changes to the risk factors disclosed in such registration statement.
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds
On November 15, 2021, we closed our initial public offering of 2,160,000 units at a price to the public of $10.00 per unit. The gross proceeds from our initial public offering, before deducting underwriting discounts and commissions, were $21.6 million. We granted the underwriter in the offering a 45-day option to purchase up to an additional 324,000 shares of common stock and/or Class A Warrants and/or Class B Warrants from the Company. The underwriter partially exercised the foregoing option to purchase an additional 324,000 Class A Warrants and 324,000 Class B Warrants. The offer and sale of all of the securities in the offering were registered under the Securities Act pursuant to a registration statement on Form S-1 (File No. 333-260029), which was declared effective by the SEC on October 5, 2021. Dawson James Securities, Inc. acted as underwriter for the offering.
There has been no material change in the planned use of proceeds from our IPO as described in our final prospectus filed with the SEC on November 12, 2021 pursuant to Rule 424(b). No direct or indirect payments were made by us to any of our directors or officers or their associates, to persons owning ten percent or more of our common stock or to their associates, or to our affiliates, other than payments in the ordinary course of business to officers for salaries. Pending the uses described, we intend to invest the net proceeds in short-term, interest-bearing obligations, investment-grade instruments, certificates of deposit or direct or guaranteed obligations of the U.S. government.
Item 3. Defaults Upon Senior Securities
None.
Item 4. Mine Safety Disclosures
Not applicable.
Item 5. Other Information
On December 15, 2021 the Compensation Committee of the Board of Directors increased the annual base salary of Dr. Jason Cook from $200,000 per year to $220,000 per year.
23
Item 6. Exhibits
INDEX TO EXHIBITS
| * | Filed herewith. |
| (1) | The certifications on Exhibit 32 hereto are deemed not “filed” for purposes of Section 18 of the Exchange Act or otherwise subject to the liability of that Section. Such certifications will not be deemed incorporated by reference into any filing under the Securities Act or the Exchange Act. |
24
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
Bluejay Diagnostics, Inc.
| SIGNATURE | TITLE | DATE | ||
| /s/ Neil Dey | Chief Executive Officer and Director | December 15, 2021 | ||
| Neil Dey | (principal executive officer) | |||
| /s/ Gordon Kinder | Chief Financial Officer | December 15, 2021 | ||
| Gordon Kinder | (principal financial and accounting officer) |
25
Exhibit 31.1
CERTIFICATION BY CHIEF EXECUTIVE OFFICER
I, Neil Dey, certify that:
| 1. | I have reviewed this quarterly report on Form 10-Q of Bluejay Diagnostics, Inc.; |
| 2. | Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; |
| 3. | Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; |
| 4. | The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and we have: |
| a. | designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; |
| b. | [intentionally omitted]; |
| c. | evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and |
| d. | disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting. |
| 5. | The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions): |
| a. | all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and |
| b. | any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting. |
December 15, 2021
| By: | /s/ Neil Dey | |
| Neil Dey | ||
| Chief Executive Officer | ||
| (Principal executive officer) |
Exhibit 31.2
CERTIFICATION BY CHIEF FINANCIAL OFFICER
I, Gordon Kinder, certify that:
| 1. | I have reviewed this quarterly report on Form 10-Q of Bluejay Diagnostics, Inc.; |
| 2. | Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; |
| 3. | Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; |
| 4. | The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and we have: |
| a. | designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; |
| b. | [intentionally omitted]; |
| c. | evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and |
| d. | disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting. |
| 5. | The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions): |
| a. | all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and |
| b. | any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting. |
December 15, 2021
| By: | /s/ Gordon Kinder | |
| Gordon Kinder | ||
| Chief Financial Officer | ||
| (Principal financial and accounting officer) |
Exhibit 32.1
CERTIFICATION OF CHIEF EXECUTIVE OFFICER
Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
(Subsections (a) and (b) of Section 1350, Chapter 63 of Title 18, United States Code)
Pursuant to section 906 of the Sarbanes-Oxley Act of 2002 (subsections (a) and (b) of section 1350, chapter 63 of title 18, United States Code), the undersigned officer of Bluejay Diagnostics, Inc., a Delaware corporation (the "Company"), does hereby certify, to such officer’s knowledge, that:
The quarterly report on Form 10-Q for the quarter ended September 30, 2021 (the "Form 10-Q") of the Company fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended and information contained in the Form 10-Q fairly presents, in all material respects, the financial condition and results of operations of the Company.
December 15, 2021
| By: | /s/ Neil Dey | |
| Neil Dey | ||
| Chief Executive Officer | ||
| (Principal Executive Officer) |
Exhibit 32.2
CERTIFICATION OF CHIEF FINANCIAL OFFICER
Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
(Subsections (a) and (b) of Section 1350, Chapter 63 of Title 18, United States Code)
Pursuant to section 906 of the Sarbanes-Oxley Act of 2002 (subsections (a) and (b) of section 1350, chapter 63 of title 18, United States Code), the undersigned officer of Bluejay Diagnostics, Inc., a Delaware corporation (the "Company"), does hereby certify, to such officer’s knowledge, that:
The quarterly report on Form 10-Q for the quarter ended September 30, 2021 (the "Form 10-Q") of the Company fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended and information contained in the Form 10-Q fairly presents, in all material respects, the financial condition and results of operations of the Company.
December 15, 2021
| By: | /s/ Gordon Kinder | |
| Gordon Kinder | ||
| Chief Financial Officer | ||
| (Principal financial and accounting officer) |